Two monoclonal antibodies targeting IL-17A (secukinumab, ixekizumab) and one against the IL-17 receptor (brodalumab) are approved for the treatment of “moderate-to-severe” plaque psoriasis, and these treatments have shown high quality early responses and maintenance of clinical improvement in psoriasis patients [44]. Here, IL17A is linked to psoriasis.